Journal of Medicinal Chemistry · 2023 · 22 citations · 30 references
MedicineOncologyPharmacologyCancer PharmacologyMolecular ImagingMolecular OncologyCancer BiomarkersOncology PharmacologyProstate Cancer ImagingProstate ImagingRadiopharmaceutical DesignTumor Receptor ImagingPet TracersProstate Cancer DiagnosisProstate-specific Membrane Antigen PetProstate-specific Membrane Antigen RadioligandsPsma-pet ImagingRadioactive TracersTumor Targeting SpecificityTumor Uptake Kinetics
Radioisotope-labeled prostate-specific membrane antigen (PSMA) PET tracers have gained popularity in diagnosing prostate cancer (PCa). This study aimed to improve the affinity and tumor-targeting capabilities of new PSMA tracers by increasing the number of pharmacophores that specifically bind to PSMA. Using biphenyl as a core scaffold, we investigated the relationship among spacer segments, affinity, and pharmacokinetic properties. In preclinical PET studies on mice with 22Rv1 tumors, compared with [ 68 Ga]Ga- PSMA-11 (SUV max = 3.37), [ 68 Ga]Ga- PSMA-D5 ( K i = 0.15) showed higher tumor uptake (SUV max = 3.51) and lower renal uptake (T/K = 1.84). In the first-in-human study, [ 68 Ga]Ga- PSMA-D5 effectively detected small PCa-associated lesions and distant metastases. The advantages of [ 68 Ga]Ga- PSMA-D5 include high tumor uptake, straightforward synthesis, and labeling, making it a promising PSMA PET tracer. Furthermore, [ 68 Ga]Ga- PSMA-D5 contains a DOTA chelator, allowing convenient labeling with therapeutic radionuclides such as 177 Lu and 225 Ac, providing the potential for targeted radioligand therapy in PCa.
30
Rebecca L. Siegel, Kimberly D. Miller, Hannah E. Fuchs et al. · CA A Cancer Journal for Clinicians · 2021 · 17.4K citations · Full text
Assessment of <sup>68</sup>Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer
Wolfgang P. Fendler, Jérémie Calais, Matthias Eiber et al. · JAMA Oncology · 2019 · 787 citations · Full text
Medicine, Nuclear Medicine, Oncology +17